In addition, published work [8] indicated that an anti-CD47/PD-L1 dual-targeting fusion protein IAB could restore the host’s immune response in vivo by activating both innate and adaptive immunity for more effective tumor eradication. This evidence concerns the gene CD47 and neoplasm.